The company's TRACER™ AAV capsid discovery platform has been used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Programs are advanced through a mix of wholly owned assets and collaborations with partners including Neurocrine, Novartis, Alexion and Transition Bio, with cash runway into 2028 based on current plans and collaboration reimbursements.
Cyborg Score Rationale
Most recent analyst rating is a Buy with a $11.00 price target. VY1706 tau-silencing gene therapy plans to complete GLP toxicology, file an IND, and begin first-in-human dosing in the second half of 2026. However, recent CMO resignation and stock trading near 52-week lows indicate execution risks.
Top Insights
Lead programs VY7523 (anti-tau antibody) and VY1706 (tau-silencing gene therapy) are designed to address Alzheimer's disease with 2026 clinical developments planned.
Q3 2025 results showed cash position of $229M with runway into 2028 and collaboration revenue of $13.4M.
Potential for third-party clinical readouts, notably Biogen's BIIB080 Phase 2 data expected mid-2026, to validate the tau knockdown approach.
Chief Medical Officer Toby Ferguson resigned effective February 20, 2026, with CEO assuming interim clinical development responsibilities.
Named Competitors
BIIB080 (tau-targeting therapy) — Phase 2 tau-targeting program with data expected mid-2026